Bristol (BMY) Holder Burns J W & Co INC Trimmed Holding as Share Value Rose

September 16, 2018 - By Hannah Black

Bristol-Myers Squibb Company (NYSE:BMY) LogoInvestors sentiment decreased to 0.78 in Q2 2018. Its down 0.05, from 0.83 in 2018Q1. It is negative, as 94 investors sold BMY shares while 550 reduced holdings. 108 funds opened positions while 396 raised stakes. 1.14 billion shares or 1.65% more from 1.12 billion shares in 2018Q1 were reported. Finance Advisory, a Kansas-based fund reported 9,759 shares. Intact Invest Mngmt Inc holds 0.16% or 82,100 shares in its portfolio. Fisher Asset Mngmt Ltd has invested 0.04% in Bristol-Myers Squibb Company (NYSE:BMY). Cubist Systematic Strategies Limited Liability Corp, a Connecticut-based fund reported 30,377 shares. Canandaigua Comml Bank Trust has 0.61% invested in Bristol-Myers Squibb Company (NYSE:BMY). Camarda Ltd holds 1.25% or 21,531 shares in its portfolio. Bkd Wealth Advsr Limited Company reported 13,477 shares. Moreover, Tirschwell & Loewy has 0.08% invested in Bristol-Myers Squibb Company (NYSE:BMY). Victory Management has invested 0% of its portfolio in Bristol-Myers Squibb Company (NYSE:BMY). Primecap Ca invested in 18.04M shares. Amp Capital Limited reported 0.3% of its portfolio in Bristol-Myers Squibb Company (NYSE:BMY). Trustco Bankshares N Y stated it has 1.07% in Bristol-Myers Squibb Company (NYSE:BMY). Private Trust Na accumulated 0.57% or 47,656 shares. Hbk Invs Lp, a Texas-based fund reported 693,257 shares. Wealth Planning Ltd accumulated 9,045 shares.

Since April 30, 2018, it had 1 buying transaction, and 0 insider sales for $249,948 activity.

Burns J W & Co Inc decreased its stake in Bristol (BMY) by 46.05% based on its latest 2018Q2 regulatory filing with the SEC. Burns J W & Co Inc sold 65,024 shares as the company’s stock rose 12.85% with the market. The institutional investor held 76,176 shares of the major pharmaceuticals company at the end of 2018Q2, valued at $4.22M, down from 141,200 at the end of the previous reported quarter. Burns J W & Co Inc who had been investing in Bristol for a number of months, seems to be less bullish one the $99.04B market cap company. The stock decreased 0.16% or $0.1 during the last trading session, reaching $60.69. About 3.89 million shares traded. Bristol-Myers Squibb Company (NYSE:BMY) has declined 4.27% since September 16, 2017 and is downtrending. It has underperformed by 19.89% the S&P500.

Analysts await Bristol-Myers Squibb Company (NYSE:BMY) to report earnings on October, 25. They expect $0.89 earnings per share, up 18.67 % or $0.14 from last year’s $0.75 per share. BMY’s profit will be $1.45B for 17.05 P/E if the $0.89 EPS becomes a reality. After $1.01 actual earnings per share reported by Bristol-Myers Squibb Company for the previous quarter, Wall Street now forecasts -11.88 % negative EPS growth.

More notable recent Bristol-Myers Squibb Company (NYSE:BMY) news were published by: which released: “Why Yervoy’s Resurgence Will Gain Momentum” on August 27, 2018, also with their article: “Short Sellers Back Off Major Pharma Stocks” published on September 13, 2018, published: “Natera (NTRA) Enters Agreement with Bristol-Myers (BMY) for Signatera ctDNA Assay” on September 13, 2018. More interesting news about Bristol-Myers Squibb Company (NYSE:BMY) were released by: and their article: “Bristol-Myers Squibb’s TYK2 inhibitor successful in mid-stage psoriasis study” published on September 12, 2018 as well as‘s news article titled: “Bristol-Myers Squibb Company (BMY) CEO Giovanni Caforio Presents at Morgan Stanley 16th Annual Global …” with publication date: September 13, 2018.

Bristol-Myers Squibb Company (NYSE:BMY) Ratings Coverage

Among 11 analysts covering Bristol Myers (NYSE:BMY), 2 have Buy rating, 0 Sell and 9 Hold. Therefore 18% are positive. Bristol Myers had 14 analyst reports since March 20, 2018 according to SRatingsIntel. The firm earned “Hold” rating on Friday, April 20 by Cowen & Co. The stock of Bristol-Myers Squibb Company (NYSE:BMY) has “Market Perform” rating given on Monday, July 23 by BMO Capital Markets. Atlantic Securities upgraded the stock to “Neutral” rating in Wednesday, August 8 report. Bank of America maintained Bristol-Myers Squibb Company (NYSE:BMY) rating on Tuesday, April 17. Bank of America has “Neutral” rating and $61 target. On Tuesday, April 17 the stock rating was maintained by Guggenheim with “Buy”. The firm has “Underperform” rating given on Wednesday, April 18 by BMO Capital Markets. The rating was upgraded by BMO Capital Markets to “Market Perform” on Friday, April 27. Credit Suisse maintained it with “Neutral” rating and $61 target in Friday, July 27 report. The rating was downgraded by Morgan Stanley on Tuesday, April 17 to “Equal-Weight”. The rating was maintained by Jefferies on Friday, April 13 with “Hold”.

Bristol-Myers Squibb Company (NYSE:BMY) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: